AstraZeneca PLC (ETR:ZEG)
163.10
+6.00 (3.82%)
Feb 2, 2026, 5:35 PM CET
AstraZeneca Employees
AstraZeneca had 94,300 employees as of December 31, 2024. The number of employees increased by 4,400 or 4.89% compared to the previous year.
Employees
94,300
Change (1Y)
4,400
Growth (1Y)
4.89%
Revenue / Employee
€525,362
Profits / Employee
€84,950
Market Cap
243.56B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 94,300 | 4,400 | 4.89% |
| Dec 31, 2023 | 89,900 | 6,400 | 7.66% |
| Dec 31, 2022 | 83,500 | 400 | 0.48% |
| Dec 31, 2021 | 83,100 | 7,000 | 9.20% |
| Dec 31, 2020 | 76,100 | 5,500 | 7.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 177,356 |
| Fresenius Medical Care AG | 109,916 |
| Bayer Aktiengesellschaft | 88,502 |
| Siemens Healthineers AG | 73,840 |
| Merck KGaA | 62,346 |
| Fielmann Group AG | 24,363 |
| Sartorius Aktiengesellschaft | 13,878 |
| Carl Zeiss Meditec AG | 5,784 |
AstraZeneca News
- 6 hours ago - AstraZeneca begins trading on the New York Stock Exchange - Business Wire
- 6 hours ago - AstraZeneca (AZN) Commences Trading on New York Stock Exchange - GuruFocus
- 6 hours ago - AstraZeneca (AZN) Gains EU Approval Recommendation for Imfinzi Regimen - GuruFocus
- 9 hours ago - CHMP Recommends EU Approval Of Imfinzi With FLOT Chemotherapy For Gastric And GEJ Cancers - Finanz Nachrichten
- 10 hours ago - AstraZeneca shares launch on New York Stock Exchange - Evening Standard
- 12 hours ago - AstraZeneca (AZN) to List on NYSE, Invests $15B in China - GuruFocus
- 12 hours ago - AstraZeneca lists on the NYSE on Monday, ending ADS program - Seeking Alpha
- 1 day ago - AstraZeneca is listing in New York, as Big Pharma balances the huge U.S. market with China's tempting innovation - CNBC